Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Cash & Equivalents of $62.1 million for Q1 2026, down 41.43% year-over-year from $106.1 million in Q1 2025, and up 14.43% quarter-over-quarter from $54.3 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Cash & Equivalents for 11 consecutive years, with $62.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 41.43% year-over-year to $62.1 million; the TTM figure through Mar 2026 stood at $62.1 million (down 41.43% YoY), while the FY2025 annual figure was $54.3 million, down 39.08% from the prior year.
- Cash & Equivalents improved to $62.1 million in Q1 2026 per RYTM's latest filing, from $54.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $416.1 million in Q3 2025 and bottomed at $48.0 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $116.8 million across 5 years, with a median of $106.1 million in 2025.
- Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 64.99% — and 2025, when it jumped 767.18%.
- Rhythm Pharmaceuticals' Cash & Equivalents stood at $128.0 million in 2022, then plunged by 52.81% to $60.4 million in 2023, then jumped by 47.56% to $89.1 million in 2024, then plunged by 39.08% to $54.3 million in 2025, then increased by 14.43% to $62.1 million in 2026.
- Business Quant data shows RYTM's Cash & Equivalents at $62.1 million in Q1 2026, $54.3 million in Q4 2025, and $416.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 65.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.61 Mn |
| Mar 31, 2026 | 62.14 Mn |
| Dec 31, 2025 | 54.30 Mn |
| Sep 30, 2025 | 416.10 Mn |
| Jun 30, 2025 | 136.11 Mn |
| Mar 31, 2025 | 106.10 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Sep 30, 2024 | 47.98 Mn |
| Jun 30, 2024 | 162.13 Mn |
| Mar 31, 2024 | 53.89 Mn |
| Dec 31, 2023 | 60.41 Mn |
| Sep 30, 2023 | 64.92 Mn |
| Jun 30, 2023 | 116.01 Mn |
| Mar 31, 2023 | 109.99 Mn |
| Dec 31, 2022 | 128.01 Mn |
| Sep 30, 2022 | 185.42 Mn |
| Jun 30, 2022 | 113.54 Mn |
| Mar 31, 2022 | 78.87 Mn |
| Dec 31, 2021 | 59.58 Mn |
| Sep 30, 2021 | 92.70 Mn |